Resmed (NYSE: RMD, ASX: RMD), a leading health technology company focused on sleep, breathing, and home care, has acquired VirtuOx, an independent diagnostic testing facility (IDTF) for sleep, respiratory, and cardiac conditions. The acquisition reflects Resmed’s commitment to making care more accessible, coordinated, and patient-friendly.
Key Details of the Acquisition
VirtuOx’s at-home diagnostic services will enhance Resmed’s ability to support patients earlier in their care journey. The virtual testing platform reduces barriers to diagnosis by offering fast, flexible, and affordable options, particularly for those with sleep-disordered breathing.
Improving Patient Care Pathways
“This acquisition creates a simpler, more connected pathway to care,” said Justin Leong, Chief Product Officer at Resmed. “By integrating VirtuOx’s diagnostic capabilities, we can accelerate the time between evaluation and treatment, reducing drop-off and helping more people access therapy benefits.”
The acquisition strengthens Resmed’s partnerships with healthcare providers to streamline diagnostics and alleviate bottlenecks. It also expands collaboration with home medical equipment providers to support patients in starting treatment efficiently.
Strategic Benefits
- Enhances care coordination and patient engagement
- Expands access to home-based care through digital innovation
- Creates opportunities to enter adjacent areas like insomnia treatment
- Deepens relationships with physicians, sleep labs, and medical equipment providers
VirtuOx will operate as a fully owned Resmed subsidiary, continuing under its existing brand with its leadership team in place. Financial terms were not disclosed as the acquisition isn’t material to Resmed’s financial results.
Company Background
Resmed develops life-changing health technologies with AI-powered digital health solutions and cloud-connected devices. VirtuOx provides technology-enabled diagnostic testing services for sleep and other health conditions across the United States.
